

## Publications

### 2023-Aug

Tingen HSA, Tubben A, van 't Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, van der Meer P, Slart RHJA. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review.

Eur J Nucl Med Mol Imaging. 2023 Aug 10. doi: 10.1007/s00259-023-06381-3.

Correction: Eur J Nucl Med Mol Imaging. 2023 Aug 22. doi: 10.1007/s00259-023-06408-9.

Brunger AF, van Rheenen R, Gans ROB, Hazenberg BPC, Nienhuis HLA.

How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform? Amyloid. 2023 Jun 15:1-3. doi: 10.1080/13506129.2023.2222878.

Slart RHJA, Chen W, Tubben A, Tingen HSA, Davies DR, Grogan M, Wechalekar AD, Kittleson MM, Thomson LEJ, Slomka PJ, Wechalekar K, Chareonthaitawee P.

Emerging Role of Scintigraphy Using Bone-Seeking Tracers for Diagnosis of Cardiac Amyloidosis: AJR Expert Panel Narrative Review.

AJR Am J Roentgenol. 2023 Jun 14. doi: 10.2214/AJR.23.29347.

Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T.

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.

N Engl J Med. 2023 Jul 20;389(3):239-250. doi: 10.1056/NEJMoa2303765.

van Ede ES, Hoeks MPA, Hofland J, Linssen VD, van Kuppevelt TH, Versteeg EM, Hafmans TG, Diepstra A, Kusters B, Vermorgen SMM.

Heparin-resistance in AL amyloidosis: a case report.

BMC Anesthesiol. 2023 Jun 21;23(1):217. doi: 10.1186/s12871-023-02147-4.

Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators.

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.

Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985.

Di Silvestre D, Brambilla F, Lavatelli F, Chirivì M, Canetti D, Bearzi C, Rizzi R, Bijzet J, Hazenberg BPC, Bellotti V, Gillmore JD, Mauri P.

The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis?

Cells. 2023 Feb 22;12(5):699. doi: 10.3390/cells12050699.

Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastiris E, Wechalekar A.

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.

Blood Cancer J. 2023 Jan 25;13(1):19. doi: 10.1038/s41408-023-00789-8.

### 2022

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.

Legger GE, Dermer CWE, Brunger AF, van Daele PLA, Nienhuis HLA.

The relation between C-reactive protein and serum amyloid A in patients with autoinflammatory diseases.

Pediatr Rheumatol Online J. 2022 Nov 24;20(1):106. doi: 10.1186/s12969-022-00757-9.

Banerjee S, Baur J, Daniel C, Pfeiffer PB, Hitzemberger M, Kuhn L, Wiese S, Bijzet J, Haupt C, Amann KU, Zacharias M, Hazenberg BPC, Westermark GT, Schmidt M, Fändrich M.

Amyloid fibril structure from the vascular variant of systemic AA amyloidosis.

Nat Commun. 2022 Nov 25;13(1):7261. doi: 10.1038/s41467-022-34636-4.

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.

Santema BT, Arita VA, Sama IE, Kloosterman M, van den Berg MP, Nienhuis HLA, Van Gelder IC, van der Meer P, Zannad F, Metra M, Ter Maaten JM, Cleland JG, Ng LL, Anker SD, Lang CC, Samani NJ, Dickstein K, Filippatos G, van Veldhuisen DJ, Lam CSP, Rienstra M, Voors AA.

Pathophysiological pathways in patients with heart failure and atrial fibrillation.

Cardiovasc Res. 2022 Aug 24;118(11):2478-2487. doi: 10.1093/cvr/cvab331.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.

J Card Fail. 2022 Jul;28(7):e1-e4. doi: 10.1016/j.cardfail.2021.06.012.

Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, Lavatelli F, Picken MM, Röcken C, Schönland S, Ueda M, Westermark P.

Tissue biopsy for the diagnosis of amyloidosis: experience from some centres.

Amyloid. 2022 Mar 29 (1): 8-13. doi: 10.1080/13506129.2021.1994386.

## 2021

Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y; THAOS investigators.

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Neurol Ther. 2021 Dec;10(2):753-766. doi: 10.1007/s40120-021-00258-z.

Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, Wixner J, Maurer MS, Garcia-Pavia P, Tournev I, Planté-Bordeneuve V, Chapman D, Amass L; THAOS Investigators.

Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. *JACC Heart Fail.* 2021 Oct;9(10):736-746. doi: 10.1016/j.jchf.2021.05.005.

Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M; THAOS Investigators. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. *JACC CardioOncol.* 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jacc.2021.08.009.

Santema BT, Arita VA, Sama IE, Kloosterman M, van den Berg MP, Nienhuis HLA, Van Gelder IC, van der Meer P, Zannad F, Metra M, Ter Maaten JM, Cleland JG, Ng LL, Anker SD, Lang CC, Samani NJ, Dickstein K, Filippatos G, van Veldhuisen DJ, Lam CSP, Rienstra M, Voors AA. Pathophysiological pathways in patients with heart failure and atrial fibrillation. *Cardiovasc Res.* 2021 Oct 23;cvab331. doi: 10.1093/cvr/cvab331.

Schönfelder J, Pfeiffer PB, Pradhan T, Bijzet J, Hazenberg BPC, Schönland SO, Hegenbart U, Reif B, Haupt C, Fändrich M. Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. *Amyloid.* 2021 Aug 2;1-9. doi: 10.1080/13506129.2021.1960501.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *J Card Fail.* 2021 Jul 1;S1071-9164(21)00250-5. doi: 10.1016/j.cardfail.2021.06.012. Addendum: *J Nucl Cardiol.* 2021 Aug;28(4):1769-1774. doi: 10.1007/s12350-020-02455-z. Correction: *J Nucl Cardiol.* 2021 Aug;28(4):1761-1762. doi: 10.1007/s12350-021-02711-w.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Circ Cardiovasc Imaging.* 2021 Jul;14(7):e000029. doi: 10.1161/HCI.0000000000000029.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Circ Cardiovasc Imaging.* 2021 Jul;14(7):e000030. doi: 10.1161/HCI.0000000000000030. Correction: *J Nucl Cardiol.* 2021 Aug;28(4):1763-1767. doi: 10.1007/s12350-021-02712-9.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schechter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.

Hill MM, Dasari S, Mollee P, Merlini G, Costello CE, Hazenberg BPC, Grogan M, Dispenzieri A, Gertz MA, Kourelis T, McPhail ED.

The Clinical Impact of Proteomics in Amyloid Typing.

Mayo Clin Proc. 2021 May;96(5):1122-1127. doi: 10.1016/j.mayocp.2020.12.002.

Louwsma J, Brunger AF, Bijzet J, Kroesen BJ, Roeloffzen WWH, Bischof A, Kuhle J, Drost G, Lange F, Kuks JBM, Gans ROB, Hazenberg BPC, Nienhuis HLA.

Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.

Amyloid. 2021 Mar;28(1):50-55. doi: 10.1080/13506129.2020.1815696.

Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.

Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9.

Erratum: Lancet Neurol. 2021 Feb;20(2):e2. doi: 10.1016/S1474-4422(20)30458-0.

## 2020

Jonker DL, Hazenberg BPC, Nienhuis HLA, Slart RHJA, Glaudemans AWJM, Noordzij W.

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?

J Nucl Cardiol. 2020 Oct;27(5):1774-1784. doi: 10.1007/s12350-018-01477-y.

Klaassen SHC, Veldhuisen van DJ, Nienhuis HLA, Berg van den MP, Hazenberg BPC, Meer van der P.

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Card Fail Rev. 2020 Aug 7;6:e21. doi: 10.15420/cfr.2019.16.

Slart RHJA, Glaudemans AWJM, Noordzij W, Nienhuis HLA, Hazenberg BPC.

<sup>99m</sup>Tc-aprotinin imaging in cardiac amyloidosis. Make an old tool new again?

J Nucl Cardiol. 2020 Aug 27(4):1155-1157. doi: 10.1007/s12350-019-01917-3.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization.  
J Nucl Cardiol. 2020 Apr;27(2):659-673. doi: 10.1007/s12350-019-01761-5.

Brunger AF, Nienhuis HLA, van Rheenen RWJ, Korte MR, Bijzet J, Gans ROB, Hazenberg BPC.  
Obesity-induced AA amyloidosis: A diagnosis of exclusion.  
Int J Clin Rheum 2020 15(2):26-34.

Brunger AF, Nienhuis HLA, Bijzet J, Roeloffzen WWH, Vellenga E, Hazenberg BPC.  
A Real-Life Cohort Study of Immunoglobulin Light-Chain (AL) Amyloidosis Patients Ineligible for Autologous Stem Cell Transplantation Due to Severe Cardiac Involvement or Advanced Disease.  
Amyloid. 2020 Jun;27(2):119-127. doi: 10.1080/13506129.2020.1714581.

Groothof D, Nienhuis HLA, Bijzet J, Houwerzijl EJ, van den Berg MP, Glaudemans AWJM, Slart RHJA, Hazenberg BPC.  
Regression of Bone-Tracer Uptake in Cardiac Transthyretin Amyloidosis.  
Mayo Clin Proc 2020 95(2):417-418. doi.org/10.1016/j.mayocp.2019.10.036.

Van der Bie MH, Louter L, Boots JMM, van Daele PLA, Klaassen SHC, Hazenberg BPC.  
Erfelijke en verworven transthyretine-gemedieerde amyloïdose.  
Ned Tijdschr Geneesk 2020 164:D4099.

Feenstra JG, Nienhuis HLA, Bijzet J, van der Zwaag PA, van den Berg MP, Hazenberg BPC.  
Coexistence of wild type and hereditary ATTR amyloidosis in one family.  
Amyloid. 2020 27(1):71-72. doi: 10.1080/13506129.2019.1690444.

Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC.  
Causes of AA amyloidosis: a systemic review.  
Amyloid. 2020 27(1):1-12. doi.org/10.1080/13506129.2019.1693359.

## 2019

Connolly MP, Panda S, Patris J, Hazenberg BPC.  
Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.  
Orphanet J Rare Dis. 2019 Sep 18;14(1):220. doi: 10.1186/s13023-019-1199-x.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.  
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging.  
J Card Fail. 2019 Aug 6. pii: S1071-9164(19)31397-1. doi: 10.1016/j.cardfail.2019.08.001.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.  
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.  
J Card Fail. 2019 Aug 29. pii: S1071-9164(19)31398-3. doi: 10.1016/j.cardfail.2019.08.002.

Dorbala S, Ando Y, Bokhari S, Dispenzneri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. *J Nucl Cardiol*. 2019 Aug 29. doi: 10.1007/s12350-019-01761-5.

Dorbala S, Ando Y, Bokhari S, Dispenzneri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging. *J Nucl Cardiol*. 2019 Aug 29. doi: 10.1007/s12350-019-01760-6.

Liberta F, Rennegarbe M, Räsler R, Bijzet J, Wiese S, Hazenberg BPC, Fändrich M. Morphological and primary structural consistency of fibrils from different AA patients (common variant). *Amyloid*. 2019 Sep;26(3):164-170. doi: 10.1080/13506129.2019.1628015.

Slart RHJA, Glaudemans AWJM, Noordzij W, Bijzet J, Hazenberg BPC, Nienhuis HLA. Time for new imaging and therapeutic approaches in cardiac amyloidosis. *Eur J Nucl Med Mol Imaging*. 2019 Jul;46(7):1402-1406. doi: 10.1007/s00259-019-04325-4.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S. Bortezomib based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. *Haematologica*. 2019 Mar 28. pii: haematol.2018.213900. doi: 10.3324/haematol.2018.213900.

Liberta F, Loerch S, Rennegarbe M, Schierhorn A, Westermark P, Westermark GT, Hazenberg BPC, Grigorieff N, Fändrich M, Schmidt M. Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. *Nat Commun*. 2019 Mar 7; 10(1):1104. doi: 10.1038/s41467-019-09033-z.

Saelices L, Nguyen BA, Chung K, Wang Y, Ortega A, Lee JH, Coelho T, Bijzet J, Benson MD, Eisenberg DS. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. *J Biol Chem*. 2019 Apr 12;294(15):6130-6141. doi: 10.1074/jbc.RA118.005257.

van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. *Eur Heart J*. 2019 Apr 21;40(16):1287-1293. doi: 10.1093/eurheartj/ehz057.

Slart RHJA, Glaudemans AWJM, Hazenberg BPC, Noordzij W. Imaging cardiac innervation in amyloidosis. *J Nucl Cardiol*. 2019 Feb;26(1):174-187. doi: 10.1007/s12350-017-1059-9.

## 2018

Rutten KHG, Raymakers RAP, Hazenberg BPC, Nienhuis HLA, Vellenga E, Minnema MC. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016. *Amyloid*. 2018 Dec;25(4):227-233. doi: 10.1080/13506129.2018.1536043.



Falke LL, Maas SLN, Rosati S, Logtenberg SJJ.

Dialysis associated  $\beta$ 2-microglobulin amyloidosis occurs even in the era of high-flux dialyzers.

*Amyloid*. 2018 Dec;25(4):265-266. doi: 10.1080/13506129.2018.1531391.

Jonker DL, Hazenberg BPC, Nienhuis HLA, Slart RHJA, Glaudemans AWJM, Noordzij W.

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?

*J Nucl Cardiol*. 2018 Oct 29. doi: 10.1007/s12350-018-01477-y.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C;

ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

*N Engl J Med*. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689.

Boersema PJ, Melnik A, Hazenberg BPC, Rezeli M, Marko-Varga G, Kamiie J, Portelius E, Blennow K, Zubarev RA, Polymenidou M, Picotti P.

Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date.

*J Proteome Res*. 2018 Dec 7;17(12):4072-4084. doi: 10.1021/acs.jproteome.8b00401.

Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, Ceriani L, Prior JO, Giovanella L, Slart RHJA.

Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

*Eur J Nucl Med Mol Imaging*. 2018 Oct;45(11):1945-1955. doi: 10.1007/s00259-018-4013-4.

Clark CC, Mebius MM, de Maat S, Tielens AGM, de Groot PG, Urbanus RT, Fijnheer R, Hazenberg BPC, van Hellemond JJ, Maas C.

Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma.

*Thromb Haemost*. 2018 Mar;118(3):471-479. doi: 10.1055/s-0038-1627460.

Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC.

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.

*Am J Cardiol*. 2018 Jan 1;121(1):107-112. doi: 10.1016/j.amjcard.2017.09.029.

## 2017

Klaassen SHC, Lemmink HH, Bijzet J, Glaudemans AWJM, Bos R, Plattel W, van den Berg MP, Slart RHJA, Nienhuis HLA, van Veldhuisen DJ, Hazenberg BPC.

Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).

*Cardiovasc Pathol*. 2017 Jul - Aug; 29:19-22. doi: 10.1016/j.carpath.2017.04.002.

van Rheenen RWJ, Hazenberg BPC, Dierckx RAJO, Glaudemans AWJM.

Clinical and 123I-SAP scintigraphy findings in three members from a family affected by AGel amyloidosis.

*Amyloid*. 2017 Mar;24(sup1):155-156. doi: 10.1080/13506129.2017.1284059.

Eelsing E, Bijzet J, Hazenberg B.

Diagnostic accuracy of new indirect ELISAs for free light-chain quantification in fat tissue of patients with AL amyloidosis.

Amyloid. 2017 Mar;24(sup1):46-47.  
doi: 10.1080/13506129.2017.1284058.

Koopman T, Niedlich-den Herder C, Stegeman CA, Links TP, Bijzet J, Hazenberg BPC, Diepstra A.  
Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma.  
Am J Kidney Dis. 2017 Apr;69(4):546-549. doi: 10.1053/j.ajkd.2016.09.027.

## 2016

Nienhuis HL, Bijzet J, Hazenberg BP.  
The Prevalence and Management of Systemic Amyloidosis in Western Countries.  
Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206.

Hazenberg AJ, Hazenberg BP, Dikkers FG.  
Long-term follow-up after surgery in localized laryngeal amyloidosis.  
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2613-20. doi: 10.1007/s00405-016-4061-y.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.  
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.  
Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612.

Adams D; European Network for TTR-FAP (ATTReuNET).  
Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care.  
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S1-2. doi: 10.1097/WCO.0000000000000294.

Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T; European Network for TTR-FAP (ATTReuNET).  
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.  
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S14-26. doi: 10.1097/WCO.0000000000000289. Review.

## 2015

van der Heijden RA, Bijzet J, Meijers WC, Yakala GK, Kleemann R, Nguyen TQ, de Boer RA, Schalkwijk CG, Hazenberg BP, Tietge UJ, Heeringa P.  
Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis.  
Sci Rep. 2015 Nov 13;5:16474. doi: 10.1038/srep16474.

van den Berg MP, Slart RH, Blokzijl H, Hazenberg BP.  
Transthyretin-Derived (ATTR) Amyloidotic Cardiomyopathy After Receiving a Domino Liver Allograft.  
Circulation. 2015 Nov 3;132(18):e216-7. doi: 10.1161/CIRCULATIONAHA.115.016264.

Sjölander D, Bijzet J, Hazenberg BP, Nilsson KP, Hammarström P.  
Sensitive and rapid assessment of amyloid by oligothiophene fluorescence in subcutaneous fat tissue.  
Amyloid. 2015 Mar;22(1):19-25.  
doi: 10.3109/13506129.2014.984063. Epub 2014 Nov 19.

Bijzet J, van Gameren II, Hazenberg BPC  
Fat tissue analysis in the management of patients with systemic amyloidosis.



Amyloid and related disorders: Surgical Pathology and Clinical Correlations. Humana Press 2015 2nd Edition, Picken MM, Dogan A, Herrera GA (Eds.):229-248.

Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerd O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, oxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. *Haematologica*. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198.

Noordzij W, Glaudemans AW, Longhi S, Slart RH, Lorenzini M, Hazenberg BP, Rapezzi C. Nuclear imaging for cardiac amyloidosis.

*Heart Fail Rev*. 2015 Mar;20(2):145-54. doi: 10.1007/s10741-014-9463-6.

## 2014

Noordzij W, Glaudemans AW, Slart RH, Hazenberg BP.

Cardiac diphosphonate uptake.

*Heart*. 2014 Aug;100(15):1192, 1217. doi: 10.1136/heartjnl-2013-305465.

Noordzij W, Glaudemans AW, van Rheenen RW, Dierckx RA, Slart RH, Hazenberg BP.

Additional diagnostic value of SPECT/CT to planar Iodine-123 labeled serum amyloid P component scintigraphy in a patient with pulmonary nodular amyloidosis.

*Amyloid*. 2014 Jun;21(2):131-3. doi: 10.3109/13506129.2014.881796.

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP.

Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.

*Amyloid*. 2014 Mar;21(1):35-44. doi: 10.3109/13506129.2013.871250.

## 2013

Brugts JJ, Houtgraaf J, Hazenberg BP, Kofflard MJ.

Echocardiographic features of an atypical presentation of rapidly progressive cardiac amyloidosis.

*World J Cardiol*. 2013 May 26;5(5):154-6. doi: 10.4330/wjc.v5.i5.154.

Hazenberg BP.

Amyloidosis: a clinical overview.

*Rheum Dis Clin North Am*. 2013 May;39(2):323-45. doi: 10.1016/j.rdc.2013.02.012.

Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP.

Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis.

*Eur J Nucl Med Mol Imaging*. 2013 Jul;40(7):1095-101. doi: 10.1007/s00259-013-2375-1.

Noordzij W, Glaudemans AW, Dierckx RA, Slart RH, Boerboom AL, Hazenberg BP.

Fluorine-18 labeled fluorodeoxyglucose PET useful for therapy monitoring in localized AL amyloidosis? *Amyloid*. 2013 Jun;20(2):135-7. doi: 10.3109/13506129.2013.773888.

## 2012

Noordzij W, Glaudemans AW, Slart RH, Dierckx RA, Hazenberg BP.

Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis.

*Amyloid*. 2012 Dec;19(4):208-11. doi: 10.3109/13506129.2012.717993.

Hazenberg BP and Bijzet J, Eds

From misfolded proteins to well-designed treatment.  
XIIIth International Symposium on Amyloidosis 2012  
ISBN 978-90-821593-0-1. Groningen: GUARD, 2013: 496p.

Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, Slart RH.  
(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis.  
*Eur J Nucl Med Mol Imaging*. 2012 Oct;39(10):1609-17.

Hazenberg BP.  
Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis.  
*Amyloid*. 2012 Mar;19(1):56-7. doi: 10.3109/13506129.2011.649322.

## 2011

van Gameren II, Bijzet J, Bos R, Limburg PC, Vellenga E, Hazenberg BP.  
Measurable regression of systemic light chain (AL) amyloid in fat tissue after a response of amyloidogenic free light chain in serum.  
*Amyloid*. 2011 Jun;18 Suppl 1:94-5. doi: 10.3109/13506129.2011.574354034. Erratum in: *Amyloid*. 2011 Jun;18 Suppl 1:95.

Hazenberg BP, van Schijndel B, Bijzet J, Limburg PC, Bos R, Haagsma EB.  
Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis.  
*Amyloid*. 2011 Jun;18 Suppl 1:79. doi: 10.3109/13506129.2011.574354028. Erratum in: *Amyloid*. 2011 Jun;18 Suppl 1:79.

Bijzet J, van Gameren II, Limburg PC, Bos R, Vellenga E, Hazenberg BP.  
Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis.  
*Amyloid*. 2011 Jun;18 Suppl 1:71-2. doi: 10.3109/13506129.2011.574354025. Erratum in: *Amyloid*. 2011 Jun;18 Suppl 1:72.

Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP.  
Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome.  
*Arch Med Res*. 2011 Apr;42(3):219-25. doi: 10.1016/j.arcmed.2011.05.002.

Bos R, de Waal EG, Kuiper H, Hazenberg BP, Vellenga E.  
Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.  
*Rheumatology (Oxford)*. 2011 Oct;50(10):1925-6. doi: 10.1093/rheumatology/ker209.

## 2010

van Gameren II, Hazenberg BP, Bijzet J, Haagsma EB, Vellenga E, Posthumus MD, Jager PL, van Rijswijk MH.  
Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis.  
*Arthritis Care Res (Hoboken)*. 2010 Mar;62(3):296-301. doi: 10.1002/acr.20101.

## 2009

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.  
Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.  
*Arthritis Rheum*. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

van Gameren II, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP.  
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain.  
*Haematologica*. 2009 Aug;94(8):1094-100. doi: 10.3324/haematol.2008.004119.

Drent G, Graveland CW, Hazenberg BP, Haagsma EB.

Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. *Amyloid*. 2009;16(3):133-41. doi: 10.1080/13506120903090726.

van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. *Arthritis Rheum*. 2009 May;60(5):1324-30. doi: 10.1002/art.24492.

Hazenberg AJ, Dijkers FG, Hawkins PN, Bijzet J, Rowczenio D, Gilbertson J, Posthumus MD, Leijnsma MK, Hazenberg BP.

Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis. *Laryngoscope*. 2009 Mar;119(3):608-15. doi: 10.1002/lary.20106.

Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA.

Nuclear imaging in cardiac amyloidosis.

*Eur J Nucl Med Mol Imaging*. 2009 Apr;36(4):702-14. doi: 10.1007/s00259-008-1037-1. Review.

## 2008

Maas C, Govers-Riemslog JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarström P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF.

Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

*J Clin Invest*. 2008 Sep;118(9):3208-18. doi: 10.1172/JCI35424.

Meijer JM, Schonland SO, Palladini G, Merlini G, Hegenbart U, Ciocca O, Perfetti V, Leijnsma MK, Bootsma H, Hazenberg BP.

Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?

*Arthritis Rheum*. 2008 Jul;58(7):1992-9. doi: 10.1002/art.23617.

Lokhorst HM, Hazenberg BP, Croockewit A.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

*N Engl J Med*. 2008 Jan 3;358(1):92; author reply 92-3.

## 2007

Roelofsen H, Alvarez-Llamas G, Dijkstra M, Breitling R, Havenga K, Bijzet J, Zandbergen W, de Vries MP, Ploeg RJ, Vonk RJ.

Analyses of intricate kinetics of the serum proteome during and after colon surgery by protein expression time series.

*Proteomics*. 2007 Sep;7(17):3219-28.

Verbeek DE, Hazenberg BP, Jager PL, Kremer Hovinga TK.

[AL-amyloidosis and its treatment by eliminating the precursor protein].

*Ned Tijdschr Geneeskd*. 2007 Sep 15;151(37):2021-6. Dutch.

Haagsma EB, Van Gameren II, Bijzet J, Posthumus MD, Hazenberg BP.

Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation.

*Amyloid*. 2007 Sep;14(3):221-6.

Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gül A, Merlini G, Wiland P, Ozdogan H, Gorevic PD, Maiz HB, Benson MD, Direskeneli H, Kaarela K, Garceau D, Hauck W, Van Rijswijk MH.

Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis.

Amyloid. 2007 Jun;14(2):133-40. Erratum in: Amyloid. 2007 Dec;14(4):325.

Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group.

Eprodisate for the treatment of renal disease in AA amyloidosis.

N Engl J Med. 2007 Jun 7;356(23):2349-60.

Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, Jager PL.

Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.

J Nucl Med. 2007 Jun;48(6):865-72.

Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, Linke RP, Merlini G, Salvi F, Saraiva MJ, Singer R, Skinner M, Winter P.

Genetic microheterogeneity of human transthyretin detected by IEF.

Electrophoresis. 2007 Jun;28(12):2053-64.

Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF.

Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses.

J Thromb Haemost. 2007 Jun;5(6):1139-42.

## 2006

van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH.

Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice.

Arthritis Rheum. 2006 Jun;54(6):2015-21.

Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, Jager PL. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.

Am J Med. 2006 Apr;119(4):355.e15-24.

## 2005

van der Hilst JC, Drenth JP, Bodar EJ, Bijzet J, van der Meer JW, Simon A; International HIDS Study Group.

Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome.

Amyloid. 2005 Jun;12(2):115-9.

## 2004

Simon A, Bijzet J, Voorbij HA, Mantovani A, van der Meer JW, Drenth JP.

Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response.

J Intern Med. 2004 Sep;256(3):247-53.

Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Gateau G.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Am J Hematol. 2005 Aug;79(4):319-28. Review.

Bartels H, Dikkers FG, van der Wal JE, Lokhorst HM, Hazenberg BP.  
Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy.  
Ann Otol Rhinol Laryngol. 2004 Sep;113(9):741-8.

de Jong KP, Hoedemakers RM, Fidler V, Bijzet J, Limburg PC, Peeters PM, de Vries EG, Slooff MJ. Portal and systemic serum growth factor and acute-phase response after laparotomy or partial epatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor.  
Scand J Gastroenterol. 2004 Nov;39(11):1141-8.

Hazenberg BP, van Gameren II, Bijzet J, Jager PL, van Rijswijk MH.  
Diagnostic and therapeutic approach of systemic amyloidosis.  
Neth J Med. 2004 Apr;62(4):121-8. Review.

van Gameren II, Lokhorst H, Hazenberg BP, Vellenga E.  
Therapeutic options in systemic AL amyloidosis.  
Neth J Med. 2004 Apr;62(4):106-13. Review.

Haagsma EB, Hawkins PN, Benson MD, Lachmann HJ, Bybee A, Hazenberg BP.  
Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families.  
Amyloid. 2004 Mar;11(1):44-9.

### **2003**

Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG.  
Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages.  
Arthritis Rheum. 2003 Jan;48(1):248-54.

### **2002**

van Gameren II, Hazenberg BP, Jager PL, Smit JW, Vellenga E.  
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.  
Amyloid. 2002 Sep;9(3):165-74.

Dodé C, Hazenberg BP, Pécheux C, Cattani D, Moulin B, Barthélémy A, Gubler MC, Delpech M, Grateau G.  
Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks.  
Nephrol Dial Transplant. 2002 Jul;17(7):1212-7.

Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ.  
Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis.  
Eur Heart J. 2002 Jan;23(2):157-61.

El Mansoury TM, Hazenberg BP, El Badawy SA, Ahmed AH, Bijzet J, Limburg PC, van Rijswijk MH. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics.  
Ann Rheum Dis. 2002 Jan;61(1):42-7.

### **2001**

Poland DC, Drenth JP, Rabinovitz E, Livneh A, Bijzet J, van het Hof B, van Dijk W.  
Specific glycosylation of alpha(1)-acid glycoprotein characterizes patients with familial Mediterranean fever and obligatory carriers of MEFV.  
Ann Rheum Dis. 2001 Aug;60(8):777-80.

de Jong KP, van Gameren MM, Bijzet J, Limburg PC, Sluiter WJ, Slooff MJ, de Vries EG.  
Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients.  
Scand J Gastroenterol. 2001 Jun;36(6):636-40.

de Jong KP, von Geusau BA, Rottier CA, Bijzet J, Limburg PC, de Vries EG, Fidler V, Slooff MJ.  
Serum response of hepatocyte growth factor, insulin-like growth factor-I, interleukin-6, and acute phase proteins in patients with colorectal liver metastases treated with partial hepatectomy or cryosurgery.  
J Hepatol. 2001 Mar;34(3):422-7.

## 2000

Hazenberg BP.

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.

Cardiology. 2000;94(3):152-8.

Haagsma EB, Scheffer H, Altland K, De Jager AE, Hazenberg BP.

Transthyretin Val71Ala mutation in a Dutch family with familial amyloidotic polyneuropathy.

Amyloid. 2000 Sep;7(3):218-21.

Hazenberg BP, van Rijswijk MH.

Where has secondary amyloid gone?

Ann Rheum Dis. 2000 Aug;59(8):577-9.

van de Loosdrecht AA, van der Kleij FG, van Minnen CA, Hazenberg BP.

A homozygous M694V mutation of the MEFV gene in a patient with periodic fever and thoracic pain.

Neth J Med. 2000 Jan;56(1):21-4.

Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, Limburg PC, ten Duis HJ, Moshage H, Hoekstra HJ, Bijzet J, Zwaveling JH.

Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro.

Crit Care Med. 2000 Feb;28(2):458-61.

## 1999

Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH.

A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis.

Ann Rheum Dis. 1999 Feb;58(2):96-102.

## 1998

Reyners AK, Hazenberg BP, Haagsma EB, Tio RA, Reitsma WD, Smit AJ.

The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations.

Amyloid. 1998 Sep;5(3):193-9.

Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA.

Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.

J Nucl Med. 1998 Apr;39(4):699-706.

Drenth JP, Krebbers RJ, Bijzet J, van der Meer JW.

Increased circulating cytokine receptors and ex vivo interleukin-1 receptor antagonist and interleukin-1beta production but decreased tumour necrosis factor-alpha production after a 5-km run.

Eur J Clin Invest. 1998 Oct;28(10):866-72.



## 1994

Kamphuis AG, Geerlings W, Hazenberg BP, Thijn CJ.

Annual evaluation of hip joints and hands for radiographic signs of A beta 2M-amyloidosis in long-term hemodialysis patients.

Skeletal Radiol. 1994 Aug;23(6):421-7.

Hazenberg BP, van Rijswijk MH.

Clinical and therapeutic aspects of AA amyloidosis.

Baillieres Clin Rheumatol. 1994 Aug;8(3):661-90. Review.

Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, Moore EG, Pepys MB.

Rapid automated enzyme immunoassay of serum amyloid A.

Clin Chem. 1994 Jul;40(7 Pt 1):1284-90.

## 1993

Heslinga HT, Hazenberg BP, Peters FT, Elema JD, Steensma JT, van Rijswijk MH.

[Amyloidosis as cause of severe abdominal symptoms in a young Somali immigrant?].

Ned Tijdschr Geneesk. 1993 Mar 27;137(13):667-72. Dutch.

## 1992

Witteveen EM, Janssen HL, Hazenberg BP, Janssen S.

[Amyloidosis; pathogenesis and therapy].

Ned Tijdschr Geneesk. 1992 Nov 21;136(47):2318-22. Review. Dutch.

van der Naalt J, Haaxma-Reiche H, van den Berg AP, Hazenberg BP, Molenaar WM.

Acute neuromyopathy after colchicine treatment.

Ann Rheum Dis. 1992 Nov;51(11):1267-8.

Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP.

Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.

J Rheumatol. 1992 Apr;19(4):621-2. Review.

Dofferhoff AS, Bom VJ, de Vries-Hospers HG, van Ingen J, vd Meer J, Hazenberg BP, Mulder PO, Weits J.

Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.

Crit Care Med. 1992 Feb;20(2):185-92.

Hamer JP, Janssen S, van Rijswijk MH, Lie KI.

Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis.

Eur Heart J. 1992 May;13(5):623-7.

## 1991

Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH.

Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes.

Biochim Biophys Acta. 1991 Feb 19;1091(3):405-8.

## 1990

Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E.

Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis.

Eur J Nucl Med. 1990;16(8-10):663-70.

## 1989

Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E.  
Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor.  
Simultaneous induction of interleukin-6 release and flare-up of the arthritis.  
Blood. 1989 Dec;74(8):2769-70.

#### **1988**

Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, Aarden LA, Yap SH.  
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes.  
Biochem Biophys Res Commun. 1988 Aug 30;155(1):112-7.

Mandema E.

[Amyloidosis].

Verh K Acad Geneeskd Belg. 1988;50(3):274-91. Review. Dutch. No abstract available.

ter Borg EJ, Janssen S, van Rijswijk MH, Bijzet J, de Jong PE, Elema JD, Kallenberg CG.  
AA amyloidosis associated with systemic lupus erythematosus.  
Rheumatol Int. 1988;8(3):141-3.

Heeg JE, van Rijswijk MH, Hazenberg BP, van Leeuwen MA.

Churg-Strauss syndrome with severe polyradiculoneuropathy and unilateral nerve deafness.

Neth J Med. 1988 Apr;32(3-4):185-93.

#### **1986**

Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK.

Systemic amyloidosis: a clinical survey of 144 cases.

Neth J Med. 1986;29(11):376-85. No abstract available.

#### **1985**

Janssen S, Elema JD, van Rijswijk MH, Limburg PC, Meijer S, Mandema E.

Classification of amyloidosis: immunohistochemistry versus the potassium permanganate method in differentiating AA from AL amyloidosis.

Appl Pathol. 1985;3(1-2):29-38.

Ockhuizen T, Westra H, Bijzet J, Post J, van Leeuwen M, van Rijswijk M.

Immunoglobulin allotypes are not involved in systemic amyloidosis.

J Rheumatol. 1985 Aug;12(4):742-6.

#### **1984**

Janssen S, van Rijswijk MH, Piers DA, de Jong GM.

Soft-tissue uptake of <sup>99m</sup>Tc-diphosphonate in systemic AL amyloidosis.

Eur J Nucl Med. 1984;9(12):538-41.

#### **1983**

van Rijswijk MH, Ruinen L, Donker AJ, de Blécourt JJ, Mandema E.

Dimethyl sulfoxide in the treatment of AA amyloidosis.

Ann N Y Acad Sci. 1983;411:67-83. No abstract available.

#### **1979**

van Rijswijk MH, van Heusden CW.

The potassium permanganate method. A reliable method for differentiating amyloid AA from other forms of amyloid in routine laboratory practice.

Am J Pathol. 1979 Oct;97(1):43-58.

van Rijswijk MH, Donker AJ, Ruinen L.  
Dimethylsulphoxide in amyloidosis.  
Lancet. 1979 Jan 27;1(8109):207-8. No abstract available.

van Rijswijk MH, Donker AJ, Ruinen L, Marrink J.  
Treatment of renal amyloidosis with dimethylsulphoxide (DMSO).  
Proc Eur Dial Transplant Assoc. 1979;16:500-5.

#### **1972**

Ruinen L, Smit-van Dijk W, Pros M, Scholten JH, Mandema E.  
The binding of Congo red and toluidine blue to isolated amyloid.  
Acta Pathol Microbiol Scand Suppl. 1972;233:122-7. No abstract available.

#### **1971**

Scholten JH, van der Slikke LB, Ruinen L, Mandema E.  
A case of recurrent polyserositis with amyloidosis and steatorrhoea in a Dutch boy.  
Folia Med Neerl. 1971 Aug-Sep;14(4):130-8. No abstract available.

#### **1967**

Scholten JH.  
[Familial hereditary amyloidosis].  
Folia Med Neerl. 1967;10(1):10-6. Dutch. No abstract available.

#### **1965**

Boéré H, Ruinen L, Scholten JH.  
Electron microscopic studies on the fibrillar component of human splenic amyloid.  
J Lab Clin Med. 1965 Dec;66(6):943-51. No abstract available.

#### **1964**

Scholten JH, Veeger W, Ten Thije O, Mandema E.  
[Diagnosis of amyloidosis by biopsy, especially rectal biopsy].  
Ned Tijdschr Geneeskd. 1964 Jan 11;108:81-4. Dutch. No abstract available.